Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Johnson and Johnson
Express Scripts
Moodys
Dow

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,362,231

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,362,231
Title:RNA interference mediating small RNA molecules
Abstract: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3' ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.
Inventor(s): Tuschl; Thomas (Brooklyn, NY), Elbashir; Sayda Mahgoub (Cambridge, MA), Lendeckel; Winfried (Hohengandern, DE)
Assignee: Max-Planck-Gesellschaft zur Foderung der Wissenschaften E.V. (Munich, DE) Massachusetts Institute of Technology (Cambridge, MA) Whitehead Institute for Biomedical Research (Cambridge, MA) University of Massachusetts (Boston, MA)
Application Number:12/683,081
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,362,231

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Alnylam Pharms Inc ONPATTRO patisiran sodium SOLUTION;INTRAVENOUS 210922-001 Aug 10, 2018 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,362,231

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
00126325Dec 1, 2000

International Family Members for US Patent 8,362,231

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 373724   Start Trial
Austria 450621   Start Trial
Austria 542899   Start Trial
Australia 2001249622   Start Trial
Australia 2002235744   Start Trial
Australia 2007203385   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
McKinsey
Boehringer Ingelheim
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.